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Bone mineral density (BMD) is determined by bone remodeling processes regulated by
endocrine, autocrine and genetic mechanisms. Thus, some studies have reported that BMD
is associated with single nucleotide polymorphisms (SNPs) associated with vitamin D recep-
tor (VDR), serum 25(OH)D levels and estrogen receptor 1 (ESR1), but without consensus.
Therefore, we aimed to map and compare the risk genotypes for forearm and total hip low
BMD.
Methods and findings
Data were derived from a population-based study in northern Norway; the Tromsø Study.
Distal forearm BMD was measured with a single x-ray absorptiometric device, while total
hip BMD was measured with a dual-energy x-ray absorptiometric device. There were 7,317
and 4,082 successful analyses of distal forearm and total hip BMD, respectively, and at
least one SNP of interest. We evaluated plausible BMD modulating factors and associa-
tions of BMD and SNPs related to vitamin D metabolism (FokI, Cdx2, BsmI, rs2298850,
rs10741657, rs3794060, rs6013897), ApaI-BsmI-TaqI haplotypes and ESR1 SNP
rs4870044.
Results
Age, BMI, physical activity and smoking were significantly associated with BMD. In a linear
regression model with adjustment for age and gender and with the major homozygote as ref-
erence, rs6013897 had a standardized beta coefficient (β) of –0.031 (P = 0.024) for total hip
BMD. β for ESR1 SNP rs4870044 was –0.016 (P = 0.036) for forearm BMD and –0.034 (P =
0.015) for total hip BMD. The other SNPs nor serum 25(OH)D were significantly associated
with BMD.
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Conclusions
Both forearm and total hip BMD were associated with ESR1 SNP rs4870044. Of the vitamin
D–related genes, only CYP24A1 gene rs6013897 was associated with total hip BMD, but
the association was weak and needs confirmation in other studies. Serum 25(OH)D was not
associated with BMD in our population, probably due to the generally sufficient vitamin D
levels in the population.
Introduction
Osteoporosis, characterized by low bone mineral density (BMD), is a global health problem
[1]. BMD is a multifactorial trait and in 50–90% of cases is possibly determined by genetic fac-
tors [2,3]. Every new identified factor may improve the prevention and treatment of bone loss,
with future individual-tailored approaches.
Vitamin D action in bone homeostasis is explained by the modulation of gene expression
and the activation of second-messenger systems when 1,25-dihydroxyvitamin D (1,25(OH)D)
binds to and activates the vitamin D receptor (VDR) [4,5]. VDR is found in all tissues involved
in vitamin D–related calcium homeostasis [4] and bone maintenance [6]: the parathyroid
gland, small intestine, kidney and bone [4]. Consequently, vitamin D levels [7] and defects or
changes in VDR function [8] are associated with bone mineralization alterations.
Recently, BMD associations with VDR-related single nucleotide polymorphisms (SNPs)
have been reported [2]. The risk of osteoporosis and the response to vitamin D may vary due
to these genetic variations, although the genetic effects may be small. Nevertheless, the VDR
SNP Cdx2 genotype (rs11568820, g.47908762C>G (chr12, GRCh38.p7) seems to be associated
with risk of fracture [9] as are some VDR SNP haplotypes (BsmI-ApaI-TaqI) [10]. However,
Uitterlinden et al.’s meta-analysis reported no clear association between VDR SNPs and BMD
[9].
Though the genetically determined heritability of serum 25(OH)D is reported to be ~43%
[3], VDR SNPs do not seem to determine serum 25(OH)D levels [11,12]. The associations
between other vitamin D related SNPs and serum 25(OH)D levels are inconsistent and with
potentially limited influence under the physiological conditions [12,13].
Another active substance, estrogen, is known to be bone-protective by acting via the estro-
gen receptor 1 (ESR1) expressed in osteoblasts and osteoclasts [14,15]. Several SNPs in the
6q25 locus related to ESR1 are reported to be associated with total hip BMD [16], but no stud-
ies regarding forearm BMD and ESR1-associated SNP rs4870044 (g.151580274C>T (chr6,
GRCh38.p7)) have been published.
As regional and interracial genetic differences may be present and mapped risk genes may
be useful as therapeutic targets, we aimed to investigate whether SNPs associated with VDR,
ESR1 and vitamin D levels could be risk factors for low forearm and total hip BMD in 7,317
and 4,082 Norwegians respectively.
Materials and methods
Study population
The Tromsø Study initiated in 1974 is a longitudinal, population-based multipurpose Norwe-
gian study conducted every 6–7 years in the Tromsø municipality. For the fourth survey
(Tromsø 4) in 1994–1995, all individuals age 25 years or older were invited; 77% (or 27,158
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subjects) participated [17]. Distal forearm BMD was successfully measured in 7,828, as 120
subjects were excluded due to movement artifacts or unfulfilled informed consent [18].
Total hip BMD was successfully measured in 4,605 subjects in the fifth survey (Tromsø 5)
in 2001–2002 (695 subjects were excluded due to ineligible scans) [19]. The participants of
Tromsø 5 were either the individuals with BMD measurements from Tromsø 4 (7,386 sub-
jects), or the randomly selected group age 30–75 years (2,967 subjects) with an attendance rate
of 79% (or 8,130 subjects).
In Tromsø 4, 11,752 subjects (selected based on subsequent endpoints of interest or as con-
trols) were successfully genotyped as previously described in detail [13].
Thus, 7,317 subjects (4,197 women and 3,120 men) with both successful genetic analyses
and distal forearm BMD measurements from Tromsø 4 as well as 4,082 subjects (2,440 women
and 1,642 men) with both the successful SNP analyses and total hip BMD measurements from
Tromsø 5 were included in the analyses in the present study.
Questionnaires
Information on possible BMD modulating factors [1,7] was collected from self-administered
questionnaires in Tromsø 4 and 5. Self-reported use of drugs and supplements was assessed
through questionnaires and also a written list of brand names of drugs used on regular basis
checked by health personnel at the study site (in Tromsø 4 only in subjects aged 55–74 years,
and 5.5% of participants >74 years). The data included current or previous use of estrogen
(both systemic and local, as the use of local estrogen does not eliminate the systemic effect
[20]), systemic corticosteroids, thiazide diuretics, insulin, other antidiabetic drugs, bisphos-
phonates, vitamin D (in the form of cod liver oil or vitamin D supplement use) and calcium
supplementation. In addition, self-reported early menopause (defined as age<47 years and
12 months of continuous amenorrhea), previous or current cancer, diabetes, osteoarthritis,
malabsorption (self-reported ulcer-related surgery), physical activity and current or previous
daily smoking were also registered. Physical activity was defined as the presence or absence of
light or hard physical activity for an average of 1 h per week during leisure time.
Body measurements
BMD measurements of the distal forearm were performed once only in Tromsø 4 with a single
x-ray absorptiometric device (DTX-100; Osteometer MediTech, Inc., Hawthorne, CA, USA)
in the radius and the ulna from the 8-mm point (the point where the ulna and the radius are
separated by 8 mm) and 24 mm proximally. The non-dominant arm was measured except
when it was ineligible due to foreign bodies or wounds [21].
Total hip BMD was measured once only in Tromsø 5 with a dual-energy x-ray absorptio-
metric device (GE Lunar Prodigy, LUNAR Corporation, Madison, WI, USA) [22]. The means
of the right and left hip scans were used for the analyses when available; otherwise, one-side
hip scans were used.
Due to the quality control and assessment routines described previously [23], the data on
forearm BMD were adjusted to improve precision by correcting the artifacts and long-term
drift throughout each survey and between surveys (using the European forearm phantom). All
scans were performed and reviewed by specially trained technicians in both Tromsø 4 and 5
who followed standardized protocols [21,22].
In both surveys, the subjects’ weight and height were measured while they wore light cloth-
ing without shoes. Body mass index (BMI) was calculated as weight divided by height squared
(kg/m2).
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Laboratory methods
Non-fasting blood samples were obtained for measurement of factors related to bone mass
(hyperparathyroidism, vitamin D deficiency [7,19], hyperthyroidism [24,25], chronic kid-
ney disease [26]). Serum parathyroid hormone (PTH; Tromsø 4 only; reference range 1.1–
6.8 pmol/l for subjects 50 years and 1.1–7.5 pmol/l for subjects >50 years) was measured
on an Immulite analyzer (Diagnostic Products, Los Angeles, CA, USA) based on a two-site
chemiluminescent immunometric assay with a coefficient of variation (CV) of 6–8% in the
actual range. Serum 25-hydroxyvitamin D (25(OH)D) (Tromsø 4 only; reference range 50–
90μmol/l for women and 60–100μmol/l for men) was measured. Sera were stored at –70˚C,
thawed in 2008 and analyzed with an electrochemiluminescence immunoassay in an auto-
mated clinical chemistry analyzer (Modular E170, Roche). Serum 25(OH)D values were
recalibrated according to the Vitamin D Standardization Program (VDSP) protocol based
on the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [27].
Serum thyroid-stimulating hormone (TSH; Tromsø 4 and 5; reference range 0.20–4.00
mIU/l) was analyzed with an automated clinical chemistry analyzer (Immulite 2000; DPC,
Los Angeles, CA, USA). As a covariate, TSH was divided into three groups: <0.49 mIU/l,
0.49–4.56 mIU/l and >4.56 mIU/l based on previous findings in the Tromsø population
[25]. Serum creatinine (Tromsø 4 and 5; reference range 55–100 μmol/L for women and
70–100 μmol/L for men) and serum calcium (Tromsø 4 and 5; reference range 2.20–2.60
mmol/L) were analyzed using a Hitachi Model 917 analyzer with reagents from Boehringer
Mannheim (Mannheim, Germany).
DNA was prepared with the manual isolation method from whole blood samples col-
lected during the subjects’ first visit in Tromsø 4. Genotyping was performed with the
KBioScience Allele-Specific Polymorphism (KASP) SNP genotyping system as previously
described [13].
Selection of SNPs associated with BMD and vitamin D
As defects or changes in VDR function [8] are associated with BMD, we selected the SNPs
associated with VDR function and earlier reported to be associated with BMD or fracture risk
[2,9]. Therefore we considered the following eight VDR-associated SNPs: FokI (rs2228570/
rs10735810, g.47879112A>T (chr12, GRCh38.p7)), BsmI (rs1544410, g.47846052C>G (chr12,
GRCh38.p7)), TaqI (rs731236, g.47844974A>T (chr12, GRCh38.p7), ApaI (rs7975232,
g.47845054C>G (chr12, GRCh38.p7)), Cdx2 (rs11568820)), rs7968585 (g.47838310C>T
(chr12, GRCh38.p7)), rs3782905 (g.47872384G>C (chr12, GRCh38.p7)) and rs2239179
(g.47863983T>A (chr12, GRCh38.p7)).
Levels of 25(OH)D [7] are also associated with BMD, therefore we included the SNPs
which earlier had been reported with the highest difference in mean serum 25(OH)D between
major and minor homozygotes in the vitamin D binding protein (DBP) gene (rs2298850,
g.71748550G>C (chr4, GRCh38.p7)), the gene that encodes for 25-hydroxylase (CYP2R1)
involved in the conversion of vitamin D into 25(OH)D (rs10741657, g.14893332A>T (chr11,
GRCh38.p7)), the 7-dehydrocholesterol reductase/NAD synthetase 1 gene (NADSYN) respon-
sible for the availability of 7-dehydrocholesterol in the skin (rs3794060, g.71476633C>T
(chr11, GRCh38.p7)) and the gene that encodes for 24-hydroxylase (CYP24A1) involved in the
degradation of 25(OH)D and synthesis of 1,25(OH)D (rs6013897, g.54125940T>A (chr20,
GRCh38.p7)) [13].
Finally, we included the rs4870044 SNP in locus 6q25 close to the ESR1 gene as this SNP
has been strongly associated with hip and lumbar spine BMD [16,28] but has not been studied
regarding forearm BMD.
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Statistical analyses
Statistical analyses were undertaken with IBM SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA)
to test the following hypotheses:
• Hypothesis 1. Forearm and total hip BMD in the Tromsø population is associated with mod-
ulating factors of BMD.
• Hypothesis 2. Serum 25(OH)D-related SNPs are associated with forearm and total hip BMD.
• Hypothesis 3. The ESR1 SNP rs4870044 is associated with forearm and total hip BMD.
Distribution of the continuous variables, including BMD and serum 25(OH)D, was evalu-
ated with skewness, kurtosis and visual inspection of histogram and Q-Q plots and found to be
normal. As a covariate, serum PTH was divided into quartiles [19].
To test hypothesis 1, we used forearm or total hip BMD as a dependent variable, and the
plausible modulating factors of BMDs as covariates in the linear regression model. Height was
included to adjust for the forearm BMD measurement. Missing values for self-reported param-
eters such as use of drugs and diseases/conditions were interpreted as negative values. Early
menopause and use of estrogen were included as covariates; therefore, men and women were
analyzed separately.
To test hypotheses 2 and 3, the genotype frequencies were evaluated with a chi-square test
for Hardy-Weinberg equilibrium [29]. Linkage disequilibrium (LD) was calculated using SNP
Annotation and Proxy Search [30] based on International HapMap Project data.
Trends for categorical variables across the selected SNPs were evaluated with the chi-square
test with linear-by-linear association and for the continuous variables with linear regression
adjusted for age and gender. When serum 25(OH)D was included, additional adjustments for
season (months, using dummy variables) were performed.
For significant linear trends for BMD across the SNP, the regression model was adjusted
for other variables significantly associated with BMD. Contrasts between genotypes were cal-
culated with univariate linear model, adjusted for age and gender.
For the VDR SNP haplotypes BsmI-ApaI-TaqI, we tested the interactions between the BsmI,
ApaI and TaqI genotypes with a linear regression.
The data are shown as mean ± standard deviation (SD). All tests are presented two-sided,
with the standardized beta coefficient in the regression analyses. A P value of less than 0.05
was considered statistically significant. The data are presented without Bonferroni correction
for multiple testing unless specified otherwise.
Ethics
The study was approved by the Regional Committee for Medical and Health Research Ethics
(REK Nord) (reference 2010/2913-4). Only participants with valid written consent were included.
Results
The baseline characteristics of the entire Tromsø 4 and Tromsø 5 populations and the groups
of subjects with valid BMD measurements of the forearm and hip and at least one successful
genotyping are shown in Table 1 and S1 Table.
Variables associated with forearm BMD
In 1,674 women, BMI, height, serum creatinine, serum calcium, use of vitamin D and estrogen
had a significant positive association with forearm BMD. Age, serum PTH, self-reported
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cancer, early menopause and use of calcium were negatively associated with forearm BMD in
the same group (S2 Table).
In 1,276 men, BMI and height were positively associated with forearm BMD, while age,
smoking, self-reported ulcus surgery, use of insulin and systemic cortisone had a negative asso-
ciation (S2 Table).
Serum 25(OH)D was not significantly associated with forearm BMD in either men or
women. Bisphosphonates were not included as a covariate, as there were only two users in
Tromsø 4.
Variables associated with total hip BMD
In 875 women, BMI and physical activity were positively associated with total hip BMD, while
age, serum PTH, smoking and use of bisphosphonates were negatively associated with total
hip BMD (S3 Table).
In 626 men, BMI and physical activity had a positive association with total hip BMD, while
age, smoking and self-reported ulcus surgery were negatively associated with total hip BMD
(S3 Table).
Serum 25(OH)D was not significantly associated with total hip BMD in either men or
women.
Associations between VDR SNPs and BMD
The VDR SNP Bsml was chosen for analyses as it is the most consistently associated with BMD
[2]. The VDR SNPs with high or moderate LD (r2 0.4) with BsmI were excluded (TaqI, r2 =
1.0; rs2239179 and rs7968585, r2 = 0.65; ApaI, r2 = 0.57; and rs3782905, r2 = 0.47). FokI and
Cdx2 were in low LD (r2 < 0.4) with other VDR SNPs and were included in the analyses.
However, in the linear regression model adjusted for age and gender, none of the three
selected VDR SNPs (FokI, Cdx2, BsmI) were significantly associated with BMD (Table 2).
Table 1. The baseline characteristics of the entire study population and subjects with valid BMD measurements of the forearm in Tromsø 4 and
hip in Tromsø 5, and at least one successful SNP analysis*. The TromsøStudy.
Entire Tromsø 4
population**
Genotyped and BMD measured
subjects in Tromsø 4
Entire Tromsø 5
population**
Genotyped and BMD measured
subjects in Tromsø 5
N 26,956 7,317 8,039 4,082
Age (years)a 46.9 ± 15.1 58.9 ± 10.4 59.7 ± 14.1 64.6 ± 9.6
Sex (% female) 52.5 57.4 56.8 59.8
Distal forearm BMD b 0.47 ± 0.09 0.46 ± 0.09 NA NA
Total hip BMD NA NA 0.95 ± 0.15 0.95 ± 0.15
BMI (kg/m2) 25.2 ± 3.9 25.9 ± 4.0 26.7 ± 4.3 26.8 ± 4.1
Height (cm) 168.7 ± 9.3 167.6 ± 9.2 168.0 ± 9.4 167.1 ± 9.1
Serum PTH (pmol/l) b 2.79 ± 1.43 2.8 ± 1.4 NA NA
Standardized serum 25
(OH)D (nmol/L) b
54.5 ± 11.6 54.5 ± 11.6 NA NA
Serum creatinine (μmol/L) b 67.3 ± 16.2 67.4 ± 16.5 70.6 ± 17.2 70.7 ± 16.8
Serum calcium (mmol/L) 2.38 ± 0.10 2.39 ± 0.10 2.36 ± 0.09 2.36 ± 0.09
aAge by the end of 1994 for Tromsø 4, and age by the end of 2001 for Tromsø 5.
bIn Tromsø 4, information attained only in those who attended the second visit in 1994–1995, N from 2,903 to 7,872.
* SNPs of interest include the SNPs presented in Table 2 (FokI, Cdx2, BsmI, rs2298850, rs10741657, rs3794060, rs6013897 and rs4870044).
**The number of subjects differs from the original number in description as the data in the table are presented based on the data available to the author.
NA: not available.
doi:10.1371/journal.pone.0173045.t001
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As the haplotypes (BsmI-ApaI-TaqI) were associated with BMD in the Rotterdam Study
[10], interactions between these SNPs regarding BMD were analyzed. However, in the present
study, the interactions were not found to be statistically significant.
Associations between serum 25(OH)D SNPs and total hip BMD
As expected [13], the four selected serum 25(OH)D SNPs were significantly associated with
the serum 25(OH)D levels with the difference in the means between major and minor homo-
zygotes ranging from (–)1.0 to 5.0 nmol/L (S4 Table).
In the linear regression model with adjustments for age and gender, a significant associa-
tion with BMD was found only for the CYP24A1 SNP rs6013897 for total hip (stand. beta
coeff. –0.031, P = 0.024) (Table 2). The difference between the major and minor homozygote
was 0.02 g/cm2 with P = 0.026 (Table 3).
Inclusion of serum 25(OH)D (N = 3,035) as a continuous or dichotomous variable (above/
below the 20th percentile, 43.0–50.0 nmol/L, differing according to season) or serum PTH
(continuous or divided in quartiles, N = 1,773) increased P-value above 0.05 for the negative
trend for rs6013897 and BMD. We observed the same effect after adjusting for the significantly
associated variables for total hip BMD (age, sex, BMI, physical activity, serum PTH, smoking,
use of bisphosphonates and ulcus surgery, S3 Table), with 1,656 subjects in the regression anal-
ysis. The estimated effect of rs6013897 adjusted only for age and gender in the selected groups
mentioned above was similar.
Associations between estrogen receptor SNP rs4870044 and BMD
Interactions between ESR1 SNP rs4870044 and sex regarding BMD were not significant.
Therefore, both sexes were analyzed together, adjusted for gender and age. We found signifi-
cant linear trends across the genotypes for forearm and total hip BMD measurements
Table 2. BMD trends across the SNPs analyzed with linear regression, adjusted for age and gender in Tromsø 4 and Tromsø 5.
Forearm BMD, Tromsø 4 Total hip BMD, Tromsø 5
SNP N Standardized beta coefficient N Standardized beta coefficient
Rs2228570/rs10735810 (FokI, VDR SNP) 7260 –0.014 4051 –0.021
Rs11568820 (Cdx2, VDR SNP) 7257 –0.006 4049 0.001
Rs1544410 (BsmI, VDR SNP) 7213 –0.009 4027 –0.014
Rs2298850 (DBP SNP) 7255 0.003 4047 –0.018
Rs10741657 (CYP2R1 SNP) 7257 –0.010 4050 –0.003
Rs3794060 (NAD-SYN SNP) 4897 –0.015 2510 0.002
Rs6013897 (CYP24A1 SNP) 7233 –0.006 4039 –0.031*
Rs4870044 (ESR1 SNP) 7281 –0.016* 4064 –0.034*
* P = 0.024 for rs6013897 and total hip BMD; P = 0.036 and P = 0.015 for rs4870044 and forearm or total hip BMD respectively in the linear regression
model, adjusted for age and gender, not corrected for multiple testing.
Unmarked coefficients had P > 0.05. None of the SNPs had P < 0.05 after Bonferroni correction (7 × 2 × P).
doi:10.1371/journal.pone.0173045.t002
Table 3. Comparison of means of total hip BMD across the genotypes of CYP24A1 SNP rs6013897 in Tromsø 5, adjusted for age and gender.
CYP24A1 rs6013897 genotypes N Mean±SD (g/cm2) Difference (SE) (g/cm2) Absolute P-value
Major homozygote T:T 2373 0.953±0.150 -0.006 (0.004) 0.208 (T:T vs. T:A)
Heterozygote T:A 1441 0.946±0.151 -0.015 (0.010) 0.114 (T:A vs. A:A)
Minor homozygote A:A 225 0.933±0.150 -0.021 (0.09) 0.026 (T:T vs. A:A)
doi:10.1371/journal.pone.0173045.t003
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(Table 2). The differences between major and minor homozygotes were 0.004 g/cm2 for fore-
arm BMD and 0.01 g/cm2 for total hip BMD (Table 4).
These associations between rs4870044 and total hip BMD remained statistically significant
after variables associated with total hip BMD were included (N = 1,661; age, BMI, physical
activity, smoking, serum PTH, self-reported ulcus surgery, use of bisphosphonates were
included from S3 Table). Some variables associated with forearm BMD were sex-specific, and
although interaction between the SNP and sex was not significant, we adjusted for these vari-
ables separately for each sex. In women (N = 1,792), inclusion of age, height, BMI, serum
PTH, serum creatinine, serum calcium, self-reported cancer, early menopause and use of vita-
min D, calcium and estrogen from S2 Table resulted in the same negative trend across the
rs4870044 genotypes, with P = 0.084. In men (N = 2,326), rs4870044 remained negatively asso-
ciated (P = 0.021) after adjusting for age, height, BMI, smoking, self-reported ulcus surgery
and use of insulin and systemic cortisone (from S2 Table).
Discussion
In this population-based Norwegian study, vitamin D–related SNP rs6013897 (near the
CYP24A1; the gene that encodes 24-hydroxylase) was associated with total hip BMD, with
decreasing BMD for each minor allele (A). To our knowledge, this finding is novel.
As expected, the SNP rs6013897 was associated with the serum 25(OH)D levels [12,13,31].
It was also associated with the serum PTH levels. One possible mechanism for the effect of
rs6013897 on total hip BMD could be through the changes in serum 25(OH)D and serum
PTH levels [32]; therefore, serum 25(OH)D and serum PTH were included as covariates in the
linear regression. The associations between rs6013897 and total hip BMD had the same direc-
tions, but were no longer statistically significant. The lack of statistical significance was proba-
bly due to the decreased number of subjects (3,035 subjects were adjusted for serum 25(OH)D,
and 1,773 subjects were adjusted for serum PTH). Comparing the effect of rs6013897 in 1,544
subjects (those with serum 25(OH)D measurements and full data for significantly associated
variables for total hip BMD), the point estimates for the effect of rs6013897 on total hip BMD
changed less than 11% when adding the selected variables into the model adjusted for age and
gender. Thus, as expected due to Mendelian randomization, the effect of the SNP on total hip
BMD was not due to or confounded by other variables though rs6013897 has been associated
with response to vitamin D3 [33,34].
No associations were found between other vitamin D–related SNPs and forearm or total hip
BMD. Activated VDR is heavily involved in bone tissue homeostasis [4,5], and associations
between BMD and BsmI [2], as well as BsmI-ApaI-TaqI haplotypes, Cdx2 and fracture risk [9,10],
have been reported. However, a comprehensive meta-analysis that included 26,242 subjects did
Table 4. Comparison of means of forearm and total hip BMD across the genotypes of ESR1 SNP rs4870044 in Tromsø 4 and 5, adjusted for age
and gender.
ESR1 SNP rs4870044 genotypes N Mean±SD (g/cm2) Difference (SE) (g/cm2) Absolute P-value
Forearm BMD, Tromsø 4
Major homozygote C:C 3709 0.465±0.094 -0.003 (0.001) 0.092 (C:C vs. T:C)
Heterozygote T:C 2981 0.465±0.094 -0.003 (0.003) 0.225 (T:C vs. T:T)
Minor homozygote T:T 591 0.457±0.089 -0.004 (0.003) 0.100 (C:C vs. T:T)
Total hip BMD, Tromsø 5
Major homozygote C:C 2038 0.956±0.150 -0.012 (0.004) 0.006 (C:C vs. T:C)
Heterozygote T:C 1699 0.944±0.151 -0.003 (0.008) 0.748 (T:C vs. T:T)
Minor homozygote T:T 327 0.940±0.144 -0.010 (0.008) 0.229 (C:C vs. T:T)
doi:10.1371/journal.pone.0173045.t004
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not find a clear association between VDR SNPs and BMD [9], in agreement with the present find-
ings. This does not argue against an important function of the VDR in bone metabolism but
more likely reflects that the SNP action on the VDR function has still not been established.
Similarly, the lack of a statistically significant association between serum 25(OH)D and BMD
in the present study should be interpreted with caution, as the studied population was vitamin D
sufficient; few subjects had very low serum 25(OH)D levels. In addition, only one serum 25(OH)
D measurement was performed, and although there is a large degree of tracking for the serum 25
(OH)D level [35], one measurement can hardly reflect lifelong exposure. In particular, it should
be recalled that the peak BMD in the Tromsø population was measured in 38- to 43-year-old sub-
jects [36], and the subjects had a mean age of 59–65 years. However, it is likely that the effect of
rs6013897 on serum 25(OH)D is lifelong. Although the effect on the serum 25(OH)D level by this
SNP was modest, it is a strong argument for the effect of vitamin D on bone metabolism.
This is the first report of an association between ESR1 SNP rs4870044 and forearm BMD, to
our knowledge. The rs4870044 was included in the analyses for two reasons. First, it has been
firmly established that this SNP is associated with total hip BMD [16,28], and finding the same
in the present study could be considered quality control. Second, this SNP has not previously
been associated with forearm BMD. The finding of such a significant association was no sur-
prise and reflects the effect of estrogen on all types of bone [14,15]. In addition, the association
between rs4870044 genotypes and BMD remained significant after other BMD-associated vari-
ables were included, indicating an independent effect of this ESR1-associated SNP.
Low forearm BMD and subsequently increased fracture risk [37] does not lead to the same
decreased health-related quality of life and increased mortality risk as hip fracture [38]. How-
ever, low forearm BMD is still clinically relevant because forearm BMD and consequent frac-
ture also predict future risk of fracture [39]. Although BMD measurements at the hip and
spine predict fractures better in the respective sites than forearm BMD [37], the latter measure-
ment is easier to perform when technical or physical limitations are present (eg, prosthesis,
arthritis, fractures, inability to lie still).
In addition to the main focus, the SNPs, a number of other potential modulating factors of
BMD were included, and the expected associations were found. However, as this analysis was
cross sectional, the causality of the associations must be carefully considered. For instance, the
most probable explanation for the negative association between use of calcium and BMD is
simply that patients with low BMD use calcium.
The present study has several limitations. First, our study may be biased due to population
stratification as the study participants come from one geographical region. Though the SNPs
of interest were chosen after associations were discovered in the other populations. Second, no
information on some potential modulating factors of BMD, such as anorexia, recent hyperthy-
roidism, hypogonadism, oophorectomy, neurologic disease, recent immobilization, rickets,
adrenal and renal bone disease or osteoporotic fractures, was available. Some data were based
on self-administrated questionnaires with the inherent biases. Furthermore, BMD measure-
ments of the forearm and hip were performed only once, and serum 25(OH)D and serum
PTH measurements were from Tromsø 4 only.
The present study also has several strengths. The study was population-based. Due to previ-
ous genome-wide association studies (GWASs) and meta-analyses, we could focus on a limited
number of SNPs. The serum 25(OH)D values were standardized and allowed comparison with
other studies. Finally, the Mendelian randomization method, in which genetic variants are
analyzed as proxies for lifelong differences in environmental exposure, is likely to minimize
selection bias and to decrease the possibility of confounding [40,41].
In conclusion, we found an association between the serum 25(OH)D level-associated
CYP24A1 SNP rs6013897 and total hip BMD. However, the effects of this SNP on serum 25
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(OH)D levels and BMD were small and need confirmation in other studies, in particular in
populations where vitamin D deficiency is prevalent. The ESR1-related SNP rs4870044 is asso-
ciated with forearm and total hip BMD.
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